Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

CS 231295

Next Previous
Search
Drug Profile

CS 231295

Alternative Names: CS-231295

Latest Information Update: 03 Apr 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Chipscreen Biosciences
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Protein kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Brain metastases; Glioblastoma; Pancreatic cancer; Small cell lung cancer; Triple negative breast cancer

Most Recent Events

  • 03 Apr 2025 Chipscreen Biosciences plans a phase I trial for Solid tumors (Inoperable/Unresectable, Metastatic disease, Recurrent, Late-stage disease) in China (PO) in April 2025 (NCT06902350)
  • 17 Oct 2024 National Medical Products Administration of China accepts IND application for CS 231295 for Solid tumoura in China
  • 16 Oct 2024 Chipscreen Biosciences files an IND application with the National Medical Products Administration in China for Solid tumours prior to October 2024

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top